Australia
· Delayed Price · Currency is AUD ImpediMed Statistics
Total Valuation
ImpediMed has a market cap or net worth of AUD 68.87 million. The enterprise value is 52.23 million.
| Market Cap | 68.87M |
| Enterprise Value | 52.23M |
Important Dates
The next estimated earnings date is Tuesday, April 29, 2025.
| Earnings Date | Apr 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ImpediMed has 2.03 billion shares outstanding. The number of shares has decreased by -99.65% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 2.03B |
| Shares Change (YoY) | -99.65% |
| Shares Change (QoQ) | +98,809.32% |
| Owned by Insiders (%) | 4.48% |
| Owned by Institutions (%) | 14.03% |
| Float | 1.83B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.97 |
| PB Ratio | 2.13 |
| P/TBV Ratio | 3.91 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.46 |
| EV / Sales | 4.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.57, with a Debt / Equity ratio of 0.03.
| Current Ratio | 4.57 |
| Quick Ratio | 4.19 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -283.40 |
Financial Efficiency
Return on equity (ROE) is -50.94% and return on invested capital (ROIC) is -33.93%.
| Return on Equity (ROE) | -50.94% |
| Return on Assets (ROA) | -29.71% |
| Return on Invested Capital (ROIC) | -33.93% |
| Return on Capital Employed (ROCE) | -68.12% |
| Revenue Per Employee | 139,072 |
| Profits Per Employee | -255,639 |
| Employee Count | 83 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 1.55 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.22% in the last 52 weeks. The beta is 2.57, so ImpediMed's price volatility has been higher than the market average.
| Beta (5Y) | 2.57 |
| 52-Week Price Change | -62.22% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.05 |
| Relative Strength Index (RSI) | 36.00 |
| Average Volume (20 Days) | 1,772,880 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ImpediMed had revenue of AUD 11.54 million and -21.22 million in losses. Loss per share was -0.01.
| Revenue | 11.54M |
| Gross Profit | 10.14M |
| Operating Income | -23.24M |
| Pretax Income | -21.19M |
| Net Income | -21.22M |
| EBITDA | -21.61M |
| EBIT | -23.24M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 17.69 million in cash and 1.05 million in debt, giving a net cash position of 16.65 million or 0.01 per share.
| Cash & Cash Equivalents | 17.69M |
| Total Debt | 1.05M |
| Net Cash | 16.65M |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 32.32M |
| Book Value Per Share | 0.02 |
| Working Capital | 18.11M |
Cash Flow
| Operating Cash Flow | -18.29M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 87.88%, with operating and profit margins of -201.33% and -183.82%.
| Gross Margin | 87.88% |
| Operating Margin | -201.33% |
| Pretax Margin | -183.61% |
| Profit Margin | -183.82% |
| EBITDA Margin | -187.25% |
| EBIT Margin | -201.33% |
| FCF Margin | n/a |
Dividends & Yields
ImpediMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 99.65% |
| Shareholder Yield | 99.65% |
| Earnings Yield | -30.81% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ImpediMed has an Altman Z-Score of -0.01. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.01 |
| Piotroski F-Score | n/a |